导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 4.96% | 1226/4772 |
| 近一周 | -1.15% | 2635/5490 |
| 近一月 | -4.25% | 2923/5407 |
| 近一季 | -8.96% | 4043/5201 |
| 近半年 | -8.94% | 3314/4918 |
| 近一年 | 7.86% | 1407/4355 |
| 近两年 | 62.62% | 1097/2950 |
| 近三年 | 34.46% | 851/2241 |
| 成立以来 | 112.89% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
6.64% 245/4961 |
18.81% 1342/5312 |
- - |
- - |
| 2025 | 25.35% 1717/4813 |
2.75% 1278/3635 |
1.39% 2353/4076 |
22.17% 1675/4524 |
-1.51% 2955/4813 |
| 2024 | 8.80% 1515/3463 |
-0.36% 1104/2808 |
-3.88% 1429/3014 |
14.47% 1966/3129 |
-0.76% 1513/3463 |
| 2023 | -7.77% 948/2656 |
5.46% 782/2280 |
-3.99% 997/2385 |
-4.27% 1104/2515 |
-4.86% 1196/2655 |
| 2022 | -19.22% 820/2207 |
-11.61% 534/1919 |
2.18% 1335/2016 |
-11.78% 580/2113 |
1.38% 1285/2208 |
| 2021 | 27.40% 89/1822 |
3.79% 169/1255 |
14.49% 254/1330 |
6.20% 238/1466 |
0.95% 1035/1822 |
| 2020 | 42.49% 267/1250 |
-3.73% 318/1028 |
21.56% 231/1067 |
15.86% 190/1164 |
5.09% 807/1184 |
| 2019 | - - |
- - |
- - |
2.30% 309/850 |
9.26% 242/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 浙商中证500增强C VS. 长安沪深300非周期A(740101) |